FULC Q2 2021 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+119.0% YoY

Gross Profit

-$13M-296.7% margin

Operating Income

-$20M-449.3% margin

Net Income

-$20M-448.5% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-8.5%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$138M

Total Liabilities

$27M

Stockholders' Equity

$111M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+119.0%
Gross Profit	-$13M	-$11M	-20.6%
Operating Income	-$20M	-$16M	-23.6%
Net Income	-$20M	-$16M	-25.3%